Brief: Shanghai Junshi Says NMPA Approves Toripalimab As Treatment For Renal Cell Carcinoma
07/04/2024 09:05
April 7 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* SAYS NMPA APPROVES CO'S TORIPALIMAB AS FIRST LINE
TREATMENT FOR
RENAL CELL CARCINOMA
Source text
Further company coverage: 688180.SS
(Reporting by Hong Kong newsroom)
((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab